pharmaceuticals

IMPACT FACTOR 4.3 | Indexed in: PubMed | CITESCORE 6.1

an Open Access Journal by MDPI

Quadruplex Nucleic Acid Ligands in Drug Discovery

Guest Editor:

Dr. Alexandra Paulo
University of Lisbon, Faculty of Pharmacy, iMed-Medicinal Chemistry Group, Lisbon, Portugal

Deadline for manuscript submissions:
closed (31 December 2021)

Message from the Guest Editor

The four-stranded structures formed by the guanine-rich sequences of nucleic acids (DNA or RNA), termed G-quaduplexes (G4), are emerging as very promising nanostructures in the field of medicine. Their presence in the human genome and in the genome of human pathogens, as well as their involvement in the regulation of several cellular processes, turn these nucleic acid transient structures into promising drug targets. Another quadruplex nucleic acid emerging as a drug target is the i-motif that can be formed in the complementary DNA cytosine-rich strand. In addition, G4-forming oligonucleotides are also promising agents for selective drug delivery and have high applicability in nanotechnology, due to their structural diversity, high stability, and cell permeability.

This Special Issue will address the following topics:

* Design and synthesis of quadruplex-binding small molecules and organic–metal complexes;

* Methods to study quadruplex–ligand interactions;

* Studies demonstrating the applicability of quadruplex ligands in drug discovery and in health-related nanotechnology.

pharmaceuticals

IMPACT FACTOR 4.3 | Indexed in: PubMed | CITESCORE 6.1

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter
Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com